Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/jcm10010034
Keywords
pharmacogenomics; NGS variants; personalized medicine
Categories
Funding
- European Union [754432]
- Polish Ministry of Science and Higher Education
- Marie Curie Actions (MSCA) [754432] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Pharmacogenomics, based on genomic profiles, is crucial for understanding diverse drug responses and effects in individuals, leading towards personalized medicine. Although next generation sequencing methods have provided genetic data for common medicines, the lack of clear guidelines for utilizing this data in routine treatment decisions remains a challenge.
Pharmacogenomics (PGx) is the knowledge of diverse drug responses and effects in people, based on their genomic profiles. Such information is considered as one of the main directions to reach personalized medicine in future clinical practices. Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body. Yet, the employing of technology is accompanied by big obtained data, which most of them have no clear guidelines for consideration in routine treatment decisions for patients. This review article talks about different types of NGS derived PGx variants in clinical studies and try to display the current and newly developed approaches to deal with pharmacogenetic data with/without clear guidelines for considering in clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available